Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QI-019A
- Development stage
- Phase 1
- Lead developer
- Union Hospital of Huazhong University of Science and Technology
- Modality
- Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
QI-019A is an innovative *in vivo* chimeric antigen receptor (CAR) T-cell gene therapy being developed for the treatment of relapsed or refractory multiple myeloma. Unlike traditional *ex vivo* CAR-T therapies that require leukapheresis and external cell manufacturing, QI-019A utilizes a lentiviral vector delivery system administered directly to the patient. This vector is designed to transduce and integrate into the genome of endogenous T cells, leading to the stable expression of a dual-targeting CAR transgene directed against B-cell maturation antigen (BCMA) and CD19. By generating CAR-T cells within the patient's body, QI-019A aims to simplify the treatment process and provide a potent anti-tumor response against malignant plasma cells.
- Other names
- QI-019A InjectionQI019A InjectionQI 019A Injection
02
Targets
BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on QI-019A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QI-019A.